MY-5445, a phosphodiesterase type 5 inhibitor, resensitizes ABCG2-overexpressing multidrug-resistant cancer cells to cytotoxic anticancer drugs.

Wu, Chung-Pu; Lusvarghi, Sabrina; Tseng, Pin-Jung; Hsiao, Sung-Han; Huang, Yang-Hui; Hung, Tai-Ho; Ambudkar, Suresh V

Wu, Chung-Pu; Lusvarghi, Sabrina; Tseng, Pin-Jung; Hsiao, Sung-Han; Huang, Yang-Hui; Hung, Tai-Ho; Ambudkar, Suresh V.

Afiliación

Wu CP; Graduate Institute of Biomedical Sciences, College of Medicine, Chang Gung University Tao-Yuan, Taiwan.
Lusvarghi S; Department of Physiology and Pharmacology, College of Medicine, Chang Gung University Tao-Yuan, Taiwan.
Tseng PJ; Department of Obstetrics and Gynecology, Taipei Chang Gung Memorial Hospital Taipei, Taiwan.
Hsiao SH; Laboratory of Cell Biology, CCR, NCI, NIH Bethesda, United States.
Huang YH; Graduate Institute of Biomedical Sciences, College of Medicine, Chang Gung University Tao-Yuan, Taiwan.
Hung TH; Graduate Institute of Biomedical Sciences, College of Medicine, Chang Gung University Tao-Yuan, Taiwan.
Ambudkar SV; Graduate Institute of Biomedical Sciences, College of Medicine, Chang Gung University Tao-Yuan, Taiwan.

Am J Cancer Res ; 10(1): 164-178, 2020.

Article en En | MEDLINE | ID: mdl-32064159

Palabras clave

ABCG2; MY-5445; Multidrug resistance; modulator; phosphodiesterase

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Am J Cancer Res Año: 2020 Tipo del documento: Article País de afiliación: Taiwán Pais de publicación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google